DSIP: What It Is, How It's Dosed, and How to Tell If It's Working

DSIP stands for delta sleep-inducing peptide, a nine-amino-acid peptide first isolated from rabbit brain in the 1970s and named for the delta-wave sleep it was associated with. Despite the name it is not a sedative and does not work like one. It does not knock you out, and the human research on what it actually does is small, old and inconclusive.

There is no established human dosing protocol, because DSIP has never been approved for any use. The convention you will see quoted is 100 to 300 mcg subcutaneously, 30 to 60 minutes before bed, often cycled a few weeks on and a few weeks off. Treat that as community practice rather than clinical guidance, and settle a dose with a clinician rather than from a forum.

Very short. The commonly cited figure is around 15 minutes, from in vitro work, with a time to peak of a few minutes. Binding to carrier proteins may extend how long it persists in the body, but there is no reliable published human pharmacokinetic study to settle it. Regimen charts DSIP as an explicitly labelled estimate for exactly that reason.

This is the honest puzzle at the centre of DSIP. A peptide that clears in roughly a quarter of an hour should not still be shaping sleep architecture five hours later, yet the reported effects are about a whole night. The usual explanations are carrier-protein binding extending its presence, or a triggering effect rather than a sustained one. Neither is established, which is a good reason to distrust anything that tells you confidently how long a dose lasts.

Reports vary, which is the point. Some people describe easier sleep onset from the first night and more vivid dreams; others notice nothing at all. There is no reliable published evidence establishing an onset time, so the only way to know your own answer is to compare a couple of weeks on it against a couple of weeks before it.

For some people, apparently. For others, nothing. The published human literature is a handful of small studies, mostly from the 1980s and largely in clinical populations such as chronic pain rather than healthy sleepers, and there is no modern randomised trial. That is not proof it does nothing; it means the evidence cannot tell you in advance which group you are in.

Convention is 30 to 60 minutes before bed, on the reasoning that you want it on board as you are falling asleep. It is injected subcutaneously, so food does not affect absorption, though a heavy meal near bedtime affects sleep on its own. If you are testing whether DSIP helps you, keep the timing consistent so timing is not a second variable in your own data.

It is not approved for human use anywhere. The FDA removed DSIP, alongside eleven other peptides, from its Category 2 bulk-substances list in April 2026, and its Pharmacy Compounding Advisory Committee reviewed it in July 2026. That removal is often reported as a green light. It was not: the nominations were withdrawn, there was no safety finding, and DSIP remains an unapproved new drug.

It is not a sedative and does not produce the physical dependence associated with benzodiazepines or Z-drugs. That is not the same as risk-free. It is an unapproved compound with very little human safety data, so the honest position is that long-term effects are unstudied rather than established as safe.

People commonly run it alongside CJC-1295 or oral MK-677. The practical problem with stacking is attribution: start two things at once, sleep improves, and you have learned nothing about either. If you want to know whether DSIP specifically does anything for you, change one variable at a time and give each a couple of weeks.

Get a baseline first. Track sleep quality, wake-ups and morning energy for one to two weeks before your first dose, then for two to four weeks on it, and compare the averages rather than individual nights. Sleep varies enormously night to night, so a good night after a dose tells you nothing. The comparison of averages is the only thing that does.